Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Wasp venom offers hope for cancer patients
brazilian wasp
The wasp, native to Brazil, produces a venom containing a cancer-fighting ingredient.

Study shows how toxin selectively attacks cancer cells
 
Scientists say the venom of a Brazilian wasp may one day be used in the fight against cancer.

New research reveals for the first time how a toxin contained in the venom is able to attack cancer cells, leaving normal cells unharmed.

To protect itself from predators, the social wasp Polybia paulista produces a venom containing the toxin MP1 (Polybia-MP1).

Laboratory testing has shown the toxin can inhibit the growth of bladder and prostate cancer cells, as well as the multi-drug resistant leukaemic cells.

Until now it was not understood how MP1 is able to do this without damaging normal cells. But according to new research published in the Biophysical Journal, the toxin selectively attacks lipids that are abnormally distributed across the surface of cancer cells. In a matter of seconds, this creates gaping holes, allowing molecules that are vital for cell function to escape.

Co-author Dr Paul Beales from the University of Leeds said this approach to treatment would be "an entirely new class of anti-cancer drugs" and could help develop new combination therapies, where multiple drugs are used at the same time to attack different parts of the cancer cells.

In future, the researchers plan to alter the amino acid sequence of MP1 to find out more about the peptide's structure, increasing its potential for clinical purposes.

"Understanding the mechanism of action of this peptide will help in translational studies to further assess the potential for this peptide to be used in medicine," Dr Beales explained.

"As it has been shown to be selective to cancer cells and non-toxic to normal cells in the lab, this peptide has the potential to be safe, but further work would be required to prove that."

Image © Prof. Mario Palma/Sao Paulo State University

Become a member or log in to add this story to your CPD history

RUMA CA&E extends survey deadline

News Story 1
 RUMA CA&E has extended the deadline for its online survey into vaccine availability.

Vets, SQPs, retailers and wholesalers will now have until Friday, 26 September at 5pm to submit their response.

The survey aims to further understanding into the vaccine supply challenges faced by the sector. It will also consider the short and long term impacts of disruption issues.

Insights are anonymous, and will be shared with industry stakeholders and government bodies.

The survey can be accessed here

Click here for more...
News Shorts
Dechra launches checklist for veterinary sustainability

Global animal health specialist Dechra has announced the world's first Veterinary Green Theatre Checklist (VGTC) to help make surgery more sustainable.

Endorsed by leading veterinary organisations, including the BEVA, BVNA and RCVS Knowledge, the checklist is designed to reduce the environmental footprint of veterinary care, while supporting better animal health outcomes.

The checklist was launched at the World Congress of Veterinary Anaesthesia and Analgesia in Paris and will be followed by an internal training and awareness campaign. For more information, visit dechra.com